Health & Biotech Positive results from MGC Pharma’s natural supplement study July 27, 2020 MGC Pharmaceuticals (ASX:MXC) has achieved positive safety and efficacy results from a safety and toxicology mouse study for a natural… Factor Therapeutics may finally have found its future — in veterinary imaging July 24, 2020 Nearly two years of pain for Factor Therapeutics (ASX:FTT) shareholders could be over soon with the company signing a term… Dimerix’s choice: do they partner or go it alone? July 23, 2020 Special Report: With results from the first of three clinical trials set to come in this year, shareholders are asking:… Australia’s cannabis sector is finally maturing July 23, 2020 Market watchers would know that Australia's cannabis sector has had its share of ups and downs over recent years. But… Osteopore shares fly after bagging new tech July 23, 2020 Special Report: Regenerative bone company Osteopore has secured the rights to cutting edge technology which could form the basis of… HeraMED announces new research collaboration with Mayo Clinic July 23, 2020 With project funding from a globally recognised research centre, the company is perfectly positioned to drive ahead with its HeraCARE… Zero to Hero: How Pro Medicus became a $2.7bn ASX200 stock without raising a cent July 23, 2020 Radiology software stock Pro Medicus (ASX:PME) was once a small cap trading for only around 50c a share. Fast forward to… Check up: COVID-19 is back in fashion July 23, 2020 Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 132-odd small cap health stocks… Respiri patient trial, bottom line both on track July 22, 2020 Special Report: Respiri’s patient study is on track and on budget, as the company keeps spending tightly under wraps. Respiri… The health stocks still taking a hit from COVID-19 July 22, 2020 COVID-19 has resulted in radical shifts in the health sector such as the adoption of tele-health, but the pandemic hasn't… Next» « Previous